EXCLUSIVE-NETWORKS
3.9.2021 21:25:08 CEST | Business Wire | Press release
Regulatory News:
Exclusive Networks S.A. (“Exclusive Networks” or the "Company") announces today the filing of its registration document (document d’enregistrement) with the AMF under the number I. 21-044.
The filing of the registration document is the first step in Exclusive Networks’ contemplated initial public offering on the regulated market of Euronext Paris, subject to market conditions and the approval by the AMF of the prospectus for the offering.
Commenting on today’s announcement, Jesper Trolle, Chief Executive Officer, said:
“Exclusive Networks is a global cyber security specialist, with a strong track record of profitable growth. Our proposed IPO on Euronext is a natural next step for us, and recognises three vital pillars of our success – our people, partners, and growth strategy. First, without the know-how and talent of our people, our growth would simply not be possible. Second, we have built our success on strong, enduring relationships within the complex cyber ecosystem, with vendors and channel partners. Exclusive Networks is the partner of choice for more than 240 leading vendors. Exclusive Networks supports the growth and expansion plans of vendors, offering local support to enable them to reach more than 18,000 resellers around the world. Third, we have a clear strategy in place to continue to deliver growth, and an IPO will support our mission to help drive the transition to a totally trusted digital world.
In the last 18 years we have made the journey from a small private company to a global cybersecurity specialist, with a 36% gross sales CAGR since 2013. Cybersecurity is a highly attractive market, estimated to be worth €58bn in 2020 and growing at a 9% CAGR from 2020 to 2026. The cyber ecosystem is getting more and more complex, the channel selling cyber products is fragmented, and technology is evolving very quickly to combat the growing sophistication in threats and cyber attacks. This creates demand for a cyber specialist like Exclusive Networks in the long-term, and we look forward to bringing even greater value to our vendors and partners, by executing on our mission to drive the transition to a totally trusted digital future.”
About Exclusive Networks
Exclusive Networks is a leading global specialist in innovative cybersecurity technologies, providing services to accelerate the sale of cybersecurity disruptive and digital infrastructure technologies on a global scale. Exclusive Networks helps cybersecurity vendors scale their businesses globally, and offering channel partners (such as value-added resellers, system integrators, telcos and managed service providers) expertise, disruptive technologies and services to fit the needs of their corporate customers. Exclusive Networks also works with several vendors offering solutions in specific sub-segments beyond cyber.
Exclusive Networks excels by combining global scale with local execution. With offices in 40 countries and the ability to service customers across five continents and in over 150 countries, Exclusive Networks, headquartered in France, offers a “global scale, local sale” model. This model enhances performance in local operations by providing both global and local support. This approach has enabled Exclusive Networks to (i) develop one of the world's broadest portfolios of cybersecurity solutions from over 240 leading vendors and (ii) develop a worldwide customer base, consisting of over 18,000 VARs, SIs, Telcos and MSPs, indirectly serving more than 110,000 end-customers. Over the period from 2018 to 2020, Exclusive Networks engaged in business in more than 124 countries.
Exclusive Networks’ approach enables vendors to adopt a simple and agile go-to-market model in relation to their cybersecurity and digital infrastructure solutions, while benefitting from Exclusive Networks’ local expertise and market knowledge in each jurisdiction where it operates. Exclusive Networks’ scale is equally important to its customers as their own end-users may be located in multiple regions of the world. In addition, Exclusive Networks helps its customers through its expertise in vendor selection as cybersecurity and digital infrastructure solutions become ever more complicated and keep evolving in the face of increasing cybersecurity threats.
Competitive Strengths
Exclusive Networks has the following key strengths:
- Placed at the centre of a large and fast-growing cybersecurity market
- Partner of choice for industry leaders, driving network effects
- Unique value proposition across cybersecurity ecosystem underpinned by specialisation
- Global footprint with local presence, providing access to a large and diversified customer base
- Strong track record of profitable growth at scale, with software-like attributes
- Experienced leadership team, with an entrenched entrepreneurial culture, supported by a visionary founder
Future Strategy
Exclusive Networks has historically demonstrated a strong track record of profitable growth and has a clear strategy in place, with the aim of delivering future growth. This strategy is founded on five core pillars:
- Continuing to drive the underlying growth of existing vendors in current geographies;
- Adding new geographies for existing vendors;
- Attracting new vendors to its existing services and solutions offering;
- Expanding its services and solutions offering to serve customers’ needs; and
- Pursuing value-accretive M&A.
Board of Directors
- Barbara Thoralfsson, Chairperson
- Jesper Trolle, Chief Executive Officer and Director
- Olivier Breittmayer, Non-Executive Director
- Nathalie Bühnemann, Non-Executive Director
- Michail Zekkos, Non-Executive Director
- Pierre Pozzo, Non-Executive Director
- Marie-Pierre de Bailliencourt, Non-Executive Director
Exclusive Networks’ registration document, approved by the AMF under the number I. 21-044 on 3 September 2021, is available on the website of the AMF (www.amf-france.org ) and Exclusive Networks (www.exclusive-networks-ir.com/ipo/ ).
The registration document contains a detailed description of the Company, in particular its business, strategy, financial condition and results of operations, as well as related risk factors. Exclusive Networks draws the public’s attention to the risk factors contained in Chapter 3 of the registration document.
Important Notice
This press release does not constitute a public offer to sell or purchase, or a public solicitation of an offer to sell or purchase, securities in the United States or in any other country or jurisdiction. Exclusive Networks shares may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended. Exclusive Networks does not intend to register in the United States any portion of the offering or to conduct a public offering of the shares in the United States.
No communication nor any information relating to the planned offering described in this press release or to Exclusive Networks may be distributed in any country or jurisdiction where such distribution would require registration or approval of securities. No such registration or approval has been or will be obtained outside of France. The distribution of this press release in certain countries may be prohibited under applicable law. Exclusive Networks assumes no responsibility if there is a violation of applicable law and regulation by any person.
This announcement is an advertisement and not a prospectus within the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, as amended (the “Prospectus Regulation”), also forming part of the domestic law in the United Kingdom by virtue of the European Union (Withdrawal) Act 2018 (the “EUWA ”).
With respect to the member States of the European Economic Area and to the United Kingdom, no action has been undertaken or will be undertaken to make an offer to the public of the securities referred to herein requiring a publication of a prospectus in any relevant member State other than France. As a result, the shares may not and will not be offered in any relevant member State other than France except in accordance with the exemptions set forth in Article 1(4) of the Prospectus Regulation, or under any other circumstances which do not require the publication by Exclusive Networks of a prospectus pursuant to Article 3(2) of the Prospectus Regulation, also forming part of the domestic law in the United Kingdom by virtue of EUWA, and/or to applicable regulations of that relevant member State or the United Kingdom.
In France, an offer to the public of securities may not be made except pursuant to a prospectus that has been approved by the French Financial Markets Authority (the “AMF”). The approval of the prospectus by the AMF should not be understood as an endorsement of the securities offered or admitted to trading on a regulated market.
Forward-looking statements
This press release contains forward-looking statements. These statements do not constitute a guarantee of Exclusive Networks’ actual results. Information expressed or implied by such statements relates to forecasts, growth and the business strategy of Exclusive Networks and are based on analyses of forecasted results and market estimates. By its nature, prospective information is subject to risks and uncertainties because it relates to events and depends on circumstances that may or may not occur in the future. In no event should such prospective information be understood to constitute a guarantee of Exclusive Networks’ future performance, financial condition, results of operations or actual cash flows, and changes in the markets in which Exclusive Networks operates may differ materially from those described or implied by the forward-looking statements contained in this press release. Even if Exclusive Networks’ financial condition, results of operations and cash flows and the changes in the markets in which it operates are consistent with the forward-looking statements contained in this press release, such statements may be unreliable indicators of Exclusive Networks’ actual future results or changes with respect to the Group and its markets. A description of factors that may have a significant adverse effect on Exclusive Networks’ business, financial condition or results of operations, or on its ability to achieve its targets and objectives, is contained in Chapter 3 “Risk Factors” of the registration document.
The contents of this announcement have been prepared by and are the sole responsibility of the Company.
Notes
1. Adjusted numbers, including Veracomp as if it had been acquired at 1 January 2020.
2. Financial information relating to 2018 or prior periods has been derived or extracted from the Company’s audited consolidated financial statements prepared in accordance with French GAAP and therefore may not be comparable to financial information relating to 2019 and subsequent financial periods, which are derived or extracted from the Company’s financial statements prepared in accordance with International Financial Reporting Standards.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210903005422/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
